June

8, 2015

ProMISTM Neurosciences, Inc.

------------------------------------------------Company and Deal Overview--------------------------------------------------------------
!

TM

Company. ProMIS Neurosciences, Inc., is a development stage biotech company that discovers and
develops precision diagnostics and therapeutics for early detection and effective treatment of
neurodegenerative diseases, in particular Alzheimers disease (AD) and amyotrophic lateral sclerosis (ALS).
TM
ProMIS Neurosciences, Inc. will be the new name for the company currently known as Amorfix Life
Sciences, Ltd, founded in 2004 and publicly traded as AMF on the Toronto Stock Exchange (TSX).
Re-launch, New Strategic Direction. The Companys scientific foundation is centered on the growing
knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins.
Numerous diseases exhibit protein misfolding, among them certain cancers, and several
neurodegenerative diseases, such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS) and
Parkinsons disease (PD).
Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like
strains, each strain representing a specific target against which therapeutics can be developed.
Accordingly, as its primary objective, the Company will focus on the discovery and development of
precision diagnostics and therapeutics directed against the several strains of beta-amyloid (A) in
Alzheimers.
New Management Team. The three-member senior management team will include Dr. Neil Cashman, the
Companys current Chief Scientific Officer. In addition, two pharmaceutical industry veterans and biotech
entrepreneurs, with over 60 years cumulative experience in key aspects of drug development and
commercialization plan to join the team: Eugene Williams as Executive Chairman and Dr. Elliot Goldstein
as Chief Executive Officer. Changes to the current Board of Directors are also planned to support the re-
launch and reinforce the new strategic focus.
Core Science & Technology. The re-launched company will be based around the leading science of Dr.
Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain
Research Center, Academic Director of the Vancouver Coastal Hospital ALS Center, and Scientific Director
of PrioNet Canada, a Center of Excellence Network for research into prions and prion diseases. DR.
Cashman has over 300 publications with over 10,000 citations and 45 patent applications.
For over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins and is
one of several leading researchers of strain specific protein misfolding.
Misfolded proteins showing prion-like strains include: beta-amyloid (A oligomers) in AD, superoxide
dismutase1 (SOD1) and TDP43 in ALS, alpha-synuclein in PD, and TAU in multiple neurodegenerative
diseases such as Alzheimers, chronic traumatic encephalopathy and certain forms of Parkinsons.
Intellectual Property. Based primarily on the research discoveries in Dr. Cashmans lab, the Company has
exclusive access to critical IP and proprietary know-how in the field. The Companys broad patent estate
consists of eight patent families issued or pending.
TM
Amorfix utilizes its computational discovery platform, ProMIS , to predict novel targets known as Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.
Amorfix owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently
has a preclinical monoclonal antibody therapeutic directed against this target.
Deal. The Company is seeking to raise a minimum of CDN $1.5MM, up to a maximum of CDN $2.5MM via
a private placement at CDN $0.03 per share, at a pre-money valuation of approximately CDN $2.0MM.
There are no warrants attached to this Offering, which is open to current shareholders and accredited
investors. The Offer is pending shareholder approval at the Companys Annual General Meeting scheduled
th
for June 29 , 2015.

June 8, 2015


!

Use of Proceeds. The primary objective will be to identify Alzheimers disease specific epitopes (targets)
on one or more strain specific A oligomers and file for patent protection in major jurisdictions. The
development of such IP is the essential first step on the path to creating precision diagnostics and
therapeutics against these targets in Alzheimers. In addition, the proceeds of this Offering will be used for
maintenance of the current and emerging IP estate, engagement of the new senior management team,
payment of outstanding debts, and general corporate purposes.
The Company anticipates that upon closing of this deal and successful achievement of its primary
objective, a second fund raising can be initiated 6-10 months hence at a step up in valuation.

---------------------------------------------------------Investment Highlights------------------------------------------------------------------

1)

2)

3)

TM

ProMIS Neurosciences is addressing what is probably the greatest area of unmet need in healthcare -
neurodegenerative disease, especially Alzheimer's

As other disease areas have been successfully addressed by advances in medicine, the population is aging
successfully. Alzheimer's is already an epidemic, one that will grow dramatically over the coming decades.
By age 85, more than 35% of the population suffers from symptomatic dementia. We now know that the
disease processes that lead to these symptoms start decades earlier. Today, over 5 million people in the
US and Canada suffer from clinical Alzheimer's, and over 15 million have the earliest stage disease known
as Mild Cognitive Impairment (MCI). More than 25 million have an ongoing disease process that will likely
progress to fully symptomatic dementia. The cost of illness in the US alone is $450 BB, with half of it in
medical costs, and half in cost of caregiving. These numbers are expected to triple over the next 30 years.
While there are palliative treatments, there are no effective therapies for Alzheimer's today.

Recent advances have increased confidence that we understand the scientific basis of Alzheimer's, and
are on the path to effective treatment

Abnormal, misfolded versions of two natural proteins, beta-amyloid ((A) and Tau, appear to be the root
cause of Alzheimer's disease. The proteins misfold into a toxic version often called a prion, or referred to
as prion-like (a misfolded protein). These toxic versions of proteins form tangles and fibrils, leading to
neuronal death and the cognitive decline of Alzheimer's. There have been numerous efforts over recent
years to create effective therapy by addressing these biologic pathways.
Such efforts have led to disappointment until very recently, when Biogen Idec announced results of an
early phase clinical trial late in 2014. Its product, BIIB037 (Aducanumab), generated encouraging positive
results in a phase 1 study of Alzheimer's patients. Biogen's market value was $71BB on December 1, 2014
before any public announcement about the results of BIIB037. It rose to $91BB by February 2, 2015 after
the announcement, an increase in value of $20BB, and has stayed at that level since.
These data support the notion that the right therapies, addressing misfolded A and Tau and applied early
enough in the disease, could be very effective. ProMIS Neurosciences believes that there is at least one
more iteration of improvement in these therapies that we need to take, and ProMIS will address that.

"Precision Medicine" - targeting the right drug to the right patient by using both a diagnostic and a
therapeutic together - has had dramatic positive impact in a number of diseases. It appears to be
important in Alzheimer's and neurodegenerative disease as well.

The precision medicine approach, as outlined recently in the New York Times, has led to major

June 8, 2015

4)

5)

breakthroughs in cancer treatment. Cancers are being treated based on their specific genetic mutation(s),
instead of using the traditional approach of treatment based on the organ in which the cancer first
appeared. According to the head of the FDA review division, Dr. Richard Pazdur, Conventional therapy
might give a response rate of 10-20%, the newer drug has a response rate of 50-60%................these are
response rates we havent seen before in diseases (NYT Feb 25, 2015).
Similarly, the biologic cause of cystic fibrosis, mutations of the gene coding for CFTR (cystic fibrosis
transmembrane conductance regulator), has been well known for a long time. However, only recently has
precision medicine allowed development of highly effective therapies for this devastating disease.

Vertex's product KALYDECO (ivacaftor) targets two genetic subsets of the disease. The Cystic Fibrosis

Foundation supported the products development financially, and sold its royalty rights in KALYDECO to a
third party for $3.3BB.
Recent scientific advances have shown that for each of the misfolded prion-like proteins that drive
Alzheimers (A, Tau) and ALS (SOD1, TDP43) there exist multiple distinct strains. These strains may be
associated with different rates of disease progression. If the example from other diseases also proves true
in the neurodegenerative field, then precision medicine targeting those specific strains may show similar
dramatic improvement in treatment effect.

TM
ProMIS Neurosciences is well positioned to apply the leading science and patented processes of its CSO,
Neil Cashman, to create specific diagnostics and therapeutics for distinct misfolded protein strains,
ushering in the era of precision medicine in Alzheimers and other neurodegenerative diseases.

ProMIS's goal is to build a broad IP portfolio of strain specific therapeutics and companion diagnostics
over the next 3-5 years, and advance its lead programs to the clinic. This may lead to M&A exit
opportunities on favorable terms.

--------------------------------------------Summary Investment Highlights-------------------------------------------------------------

1. There is very significant unmet need in neurodegenerative diseases, especially Alzheimers.

2. There is increased confidence that we understand the scientific basis of Alzheimer's, and are on the
path to effective treatment.
3. Precision Medicine has had dramatic positive impact in a number of diseases and appears to be
important in Alzheimer's and neurodegenerative disease as well.
4. Using the precision medicine approach, the Companys primary focus is on the discovery and
development of specific diagnostics and therapeutics for effective treatment of Alzheimers disease.
5. ProMIS's goal is to build a broad IP portfolio over the next 3-5 years, and advance its lead program to
the clinic. This may lead to M&A exit opportunities on favorable terms.

June 8, 2015

-------------------------------------------------------------Risk Factors--------------------------------------------------------------------------------------


TM

ProMIS Neurosciences competes in the highly risky healthcare market. Investors should carefully review the risk
factors, and should not invest capital they are not in a position to lose.
Risk factors include:
o
o
o
o
o
o
o
o
o
o

The re-launched company has limited operating history, and may have difficulties recruiting or retaining
qualified personnel necessary to execute the company's plans.
The company may have difficulties raising follow on financing, or may have to accept unfavorable terms.
The Company may be unable to identify relevant targets (DSEs).
IP relating to DSEs may not be granted.
Issued IP may be successfully challenged by third parties.
It may not be possible to create therapeutics and companion diagnostics targeting the DSEs.
It may not be possible to manufacture the companion diagnostics and therapeutics.
The therapeutic products and companion diagnostics may fail during development for reasons of poor
safety, lack of efficacy, or other issues.
The therapeutics and companion diagnostics may not receive regulatory approvals.
Other companies may be able to create competitive products that are better, or faster to market.



This information release may contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein, and therefore these
statements should not be read as guarantees of future performance or results. All forward-looking
statements are based on the Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this information release. Due to risks
and uncertainties, including the risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.